Hr. Prof. Dr. med. Joerg Hasford

Marchioninistr. 15, 81377 München
Telefon: Durchwahl:
+49 (0)89 / 7095-7480
Sekretariat:
+49 (0)89 / 7095-7481
Fax: +49 (0)89 / 7095-7482
E-Mail: has@ibe.med.uni-muenchen.de

Zimmer: K U1 810

Liste der Promotionen

Studium der Medizin in München und Berlin

1980 Promotion an der Freien Universität Berlin zum Dr. med. mit einer experimentellen Arbeit in der Klinischen Pharmakologie

1979-1984 Wissenschaftlicher Mitarbeiter des BZT

1984-1990 Wissenschaftlicher Leiter des Biometrischen Zentrums für Therapiestudien München

1989 Habilitation und Ernennung zum Privatdozenten für Biometrie und Epidemiologie an der Ludwig-Maximilians-Universität in München

Seit 1994 Universitäts-Professor für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie an der LMU

Seit 1996 Mitglied der Ethik-Kommission der Bayerischen Landesärztekammer, seit 2002 Vorsitzender

Seit 2006 Mitglied des Vorstands des Arbeitskreises Medizinischer Ethikkommissionen in der Bundesrepublik Deutschland, seit 2009 stellvertretender Vorsitzender

Seit 2005 Mitglied des Münchner Kompetenzzentrum Ethik

Seit 2009 Mitglied des Wissenschaftlichen Beirates zur Weiterentwicklung des Risikostrukturausgleichs beim Bundesversicherungsamt

Im Jahre 2000 Verleihung des Paul-Martini-Preis der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie, GMDS e.V.

Im Jahr 2008 Ernennung zum Fellow of the Society for Clinical Trials

Seit 2008 Editor for Europe von Pharmacoepidemiology and Drug Safety

• Methodik, Planung und Auswertung klinischer Studien
• Prognoseforschung
• Compliance und Persistence
• Arzneimittelepidemiologie und Pharmakovigilanz
• Public Health Forschung

• Methodische Betreuung der CML I, II, III, IIIA und IV-Studien
• Methodische Betreuung der AML-Intergroup-Studie
• Methodische Betreuung von Lymphom-Studien
• Kompetenznetz: Akute und Chronische Leukämien
• Network of Excellence: Acute and Chronic Leukemia
• Forschungsgruppe Pharmakoepidemiologie
  • Pharmacoepidemiological Research on Outcomes of Therapeutics (PROTECT, www.imi-protect.eu )

• L5, L6, L9 für Medizinstudenten
• Arzneimittelepidemiologie I und II für Studierende des Postgraduierten-Studiengangs Öffentliche Gesundheit und Epidemiologie
• Lehrauftrag an der ETH Zürich für Pharmacoepidemiology

Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, Göhring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Lauseker M, Pfirrmann M, Hasford J, Saussele S, Hehlmann R
Impact of ACA at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV
Blood. 2011 Oct 28 [Epub ahead of print]

Amann C, Hasford J, Stausberg J
Hospital Admission due to Adverse Drug Events (ADE): An Analysis of German Routine Hospital Data of 2006
Gesundheitswesen. 2011 Oct 20 [Epub ahead of print]

von Renteln-Kruse W, Dapp U, Anders J, Pröfener F, Schmidt S, Fertmann R, Hasford J, Minder C
The LUCAS* consortium: Objectives of interdisciplinary research on selected aspects of ageing and health care for older people in an urban community
Z Gerontol Geriatr. 2011 Aug;44(4):250-255

Stausberg J, Hasford J
Drug-related admissions and hospital-acquired adverse drug events in Germany: a longitudinal analysis from 2003 to 2007 of ICD-10-coded routine data
BMC Health Serv Res. 2011 May 29;11:134.

Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R
Predicting complete cytogenetic response and subsequent progression-free survivial in 2060 patients with CML on imatinib treatment: the EUTOS score
Blood. 2011 Jul 21;118(3):686-92. Epub 2011 May 2

Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Müller MC, Pletsch N, Proetel U, Haferlach C, Schlegelberger B, Balleisen L, Hänel M, Pfirrmann M, Krause SW, Nerl C, Pralle H, Gratwohl A, Hossfeld DK, Hasford J, Hochhaus A, Saussele S
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia
J Clin Oncol. 2011 Apr 20;29(12):1634-42. Epub 2011 Mar 21.

Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Saljé K, Mueller S, Hippius M, Thuermann PA, Hasford J, Net of Regional Pharmacovigilance Centers
Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations
Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):626-34. doi:10.1002/pds.2118. Epub 2011 Mar 8

Hasford J, Bramlage P, Koch G, Lehmacher W, Einhäupl K, Rothwell PM
Standards for subgroup analyses are needed? –we couldn’t agree more
J Clin Epidemiol. 2011 Apr;64(4):451, author reply 452. Epub 2011 Jan 12

Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T, Barosi G, Bassan R, Béné MC, Berger U, Büchner T, Burnett A, Cross NC, de Witte TJ, Döhner H, Dombret H, Einsele H, Engelich G, Foà R, Fonatsch C, Gökbuget N, Gluckman E, Gratwohl A, Guilhot F, Haferlach T, Hallek M, Hasford J, Hochhaus A, Hoelzer D, Kiladjian JJ, Labar B, Ljungman P, Mansmann U, Niederwieser D, Ossenkoppele G, Ribera JM, Rieder H, Serve H, Schrotz-King P, Sanz MA, Saussele S, European LeukemiaNet
The European LeukemiaNet: achievements and perspectives
Haematologica. 2011 Jan;96(1):156-62. Epub 2010 Nov 3.

Hasford J, Bramlage P, Koch G, Lehmacher W, Einhäupl K, Rothwell PM
Inconsistent trial assessments by the National Institute for Health and Clinical Excellence and IQWiG: standards for the performance and interpretation of subgroup analyses are needed
J Clin Epidemiol. 2010 Dec;63(12):1298-304. Epub 2010 Feb 21.

Stausberg J, Hasford J
Identification of adverse drug events: the use of ICD-10 coded diagnoses in routine hospital data
Dtsch Ärzteblatt Int. 2010 Jan;107(3):23-9. Epub 2010 Jan 15.

Hasford J, Lehmacher W
Benefit assessment in Germany
N Engl J Med. 2010 Jan 28;362(4):e11; author reply e11. No abstract available

Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J, Hehlmann R; German Study Goup
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era; evaluation of its impact within a subgroup of the randomized German CML Study IV
Blood. 2010 Mar 11;115(10):1880-5. Epub 2009 Nov 18.

Rohrbacher M, Hasford J
Epidemiology of chronic myeloid leukemia (CML).
Best Practice & Research Clinical Haematology 2009; 22(3): 295-302

Stausberg J, Hasford J
Identifikation von unerwünschten Arzneimittelwirkungen in Routinedaten
Hrsg. von ID Information und Dokumentation im Gesundheitswesen GmbH & Co KGaA, Berlin. ID Verlag Berlin, 2009. ISBN 978-3-926436-97-9.

Bramlage P, Hasford J
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review
Cardiovasc Diabetol. 2009; 8: 18. Published online 2009 March 27. doi: 10.1186/1475-2840-8-18.

Schmiedl S, Rottenkolber M, Szymanski J, Hasford J, Thuermann PA.
Declining public health burden of digoxin toxicity: decreased use or safer prescribing?
Clin Pharmacol Ther. 2009 Feb;85(2):143-4; author reply 144. Epub 2008 Dec 24.

Rohrbacher M, Berger U, Hochhaus A, Metzgeroth G, Adam K, Lahaye T, Saussele S, Müller MC, Hasford J, Heimpel H, Hehlmann R.
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
Leukemia. 2009 Mar;23(3):602-4. Epub 2008 Sep 11.

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Blood. 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25. Erratum in: Blood. 2008 Jun 15;111(12):5761.

Messerer D, Engel J, Hasford J, Schaich M, Ehninger G, Sauerland C, Büchner T, Schumacher A, Krahl r, Niederwieser D, Krauter J, Ganser A, Creutzig U, Döhner H, Schlenk RF; German AML Intergroup.
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Haematologica 2008;93:826-33.

Achenbach P, Baker J, Bonifacio E; Pre-POINT Study Group.
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization.
Curr Diab Rep 2008;8:87-93. Review

Markl GE, Strunz-Lehner C, Egen-Lappe V, Hasford J.
The Association of Psychosocial Factors with Nausea and Vomiting during Pregnancy.
J Psychosom Obstet Gynaecol 2008;29:17-22

Waller P, Beard K, Egberts T, Evans S, Hallas J, Hasford J, Laporte JR, Moore N, Shakir S, Sturkenboom M.
European commission consultation on pharmacovigilance.
Pharmacoepidemiol Drug Saf 2008;17:10-109.

Hehlmann R, Gratwohl A, Pfirrmann M, Hasford J, Hochhaus A, Hossfeld DK, Heimpel H.
Response: Drug Treatment and allografting as first-line therapy in young patients with CML.
Blood 2007;110:4618-9.

Schmiedl S, Szymanski J, Rottenkolber M, Hasford J, Thürmann PA.
Age- and gender-specific incidence of hospitalisation for digoxin intoxication.
Drug Saf 2007;30:1171-3.

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M.
A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma.
Blood 2007 (Epub ahead of print).

Markl GE, Strunz-Lehner C, Egen-Lappe V, Lack N, Hasford J.The association of psychosocial factors with nausea and vomiting during pregnancy.J Psychosom Obstet Gynaecol. 2007 Jul 5:1-6. [Epub ahead of print]

Hasford J, Schroeder-Bernhardi D, Rottenkolber M, Kostev K, Dietlein D.
Persistence with antihypertensive treatments: Results of a three year follow-up cohort study.
Eur J Clin Pharmacol 2007;63:1055-1061.

Schmiedl S, Szymanski J, Rottenkolber M, Drewelow B, Haase G, Hippius M, Reimann I, Siegmung W, Haack S, Hasford J, Thürmann P für die Deutsche Pharmakovigilanz-Studiengruppe.
Fingerhut - ein alter Hut? Eine Analyse stationärer Aufnahmen durch digitalisassoziierte unerwünschte Arzneimittelwirkungen.
Med Klinik 2007;102:603-11.

Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Loeffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH, Gratwohl A.
Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.
Blood 2007;109:4686-92.

Limmroth V, Malessa R, Zettl UK, Köhler J, Japp G, Haller P, Elias W, Obhof W, Viehover A, Meier U, Brosig A, Hasford J, Putzki N, Kalski G, Wernsdorfer C; for the QUASIMS Study Group.
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis.
J Neurol 2007;254:67-77.

Markl GE, Strunz-Lehner C, Egen-Lappe V, Hasford J.
Prescribing patterns of anti-emetic drugs during pregnancy in Germany.
Arch Gynecol Obstet 2007;275:461-7.

Thürmann P, Haack S, Werner U, Szymanski J, Haase G, Drewelow B, Reimann IR, Hippius M, Siegmund W, May K, Hasford J.
Tolerability of beta-blockers metabolized via cytochrome P450 2D6 is sex-dependent.
Clin Pharmacol Ther 2006;80:551-3.

Saussele S, Adam K, Hochhaus A, Bene MC, Büchner T, Burnett A, Finazzi G, Fonatsch C, Gluckman E, Gokbuget N, Grimwade DJ, Haferlach T, Hallek M, Hasford J, Hölzer D, Ljungman P, Niederwieser D, Serve H, Simonsson B, de Witte TJ, Hehlmann R, European LeukemiaNet.
Clinical research at the European LeukemiaNet.
Dtsch. Med Wochenschr 2006, 131;2423-6.

Thürmann P, Scymanski J, Drewelow B, Haase G, Hippius M, Reimann I, Siegmund W, May K, Hasford J.
Drug-related hospital admissions at the German pharamcovigilance centers (PVCs).
Acta Pharmacol Sin 2006; 27: 201 (abstract).

Hasford J, Virchow J.C.
Excess mortality in patients with asthma on long acting beta2-agonists.
Eur Respir J 2006;28:900-2.

Molter-Bock E, Hasford J, Pfundstein T.
Psychopharmakologische Behandlungspraxis in Münchener Altenheimen.
Z Gerontol Geriat 2006;39:336-43.

Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J, Young L, Bartlett B, Neuner C, Fischer KH, Neuman B, Wurzner R, Grubeck-Loebenstein B.
Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers.
Vaccine 2006;24:6808-11.

Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W for the German Low Grade Lymphoma Study Group (GLSG).
The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with Rituximab and the combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) with respect to treatment outcome.
Blood 2006;108:1504-1508.

Amann U, Egen-Lappe V, Strunz-Lehner C, Hasford J.
Antibiotics in pregnancy: analysis of potential risks and determinants in a large German statutory sickness fund population.
Pharmacoepidemiol drug saf 2006;15:327-337.
 
Maywald O, Pfirrmann M, Berger U, Breitscheidel L, Gratwohl A, Kolb H-J, Beelen DW, Tobler A, Metzgeroth G, Gnad SU, Hochhaus A, Hasford J, Hehlmann R, Reiter A for the German CML Study Group and theSwiss group of Clinical Cancer Research (SAKK).
Cytogenetic response to prior treatment with interferon-a is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
Leukemia. 2006 Mar;20(3):477-84
 
Pfirrmann M, Hasford J.
A prognostic score including the time-dependent variable cytogenetic remission for risk-stratified comparison of survival between imatinib-treated patients and historical control data on IFN-treament.
haematologica/the hematology journal 2005;90(Suppl.2):43. (abstract).
 
Hasford J.
Common Treatment Arms and Uniform Protocol Standards: A New Mulitcenter Trial Design.
Clinical Trials 2005;2:S67. (abstract).
 
Berger U, Hochhaus A, Pfirrmann M, Schoch C, Reiter A, Ehninger G, Fischer T, Gratwohl A, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Krause S, Nerl C, Pralle H, Tobler A, Hehlmann R, The German CML-Study Group.H.
Concept, Feasibility and Results of the Randomized Comparison of Imatinib Combination Therapies for Chronic Myeloid Leukemia: The German CML-Study IV.
Blood 2005;106;11:315a-316a.
 
Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W.
The Follicular Lymphoma International Prognostic Index (FLIPI) Predicts Treatment Outcome in Patients with Advanced Stage Follicular Lymphoma Treated Front-Line with Rituximab and the Combination of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP).
Blood 2005;106;272a.
 
Messerer D, Engel J, Hasford J, Schaich M, Soucek S, Ehninger G, Sauerland C, Büchner T, Niederwieser DW, Krahl R, Krauter J, Schäfer I, Ganser A, Schleich C, Döhner H, Schlenk RF.
Allogeneic Transplanation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.
Blood 2005;106;221a.
 
Heldwein W, Dollhopf M, Rosch T, Meining A, Schmidtsdorff G, Hasford J, Hermanek P, Burlefinger R, Birkner B, Schmitt W.
The Munich Polypectomy Study (MUPS): Prospective Analysis of Complications and Risk Factors in 4000 Colonic Snare Polypectomies.
Endoscopy 2005;37:1116-22.

Pfirrmann M, Hasford J.
A Simulation Study Using Validated Prognostic Factors to Assess Expected Long-term Survival.
Methods Inf Med 2005;44;577-583.
 
Hasford J.
Letter to the editor. Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (CopaxoneÒ) by J. Hass and M. Firzlaff
Eur Journal of Neur 2005;12:916-917.

Hasford J. CONTRA medikamentöse Alzheimer Therapie – Die Datenlage ist unzureichend!
Der Neurologe & Psychiater DNP 2005;9:11.
 
Strunz-Lehner C, Egen-Lappe V, Pfirrmann M, Koethemann M , Hasford J.
Socioeconomic factors influencing the prescribing of drugs for pregnant women: a prospective cohort study based on sickness fund data.
Pharmacoepidemiol Drug Saf 2005;14:S30.
 
Hasford J.
Evaluation of the appropriateness of use of over the counter drugs.
Pharmacoepidemiol Drug Saf 2005;14:S12.
 
Schuster DM, Egen-Lappe V, Strunz-Lehner C, Koethemann M, Hasford J.
Prescribing of analgesics, antirheumatics an migraine therapeutics during pregnancy in Germany.
Pharmacoepidemiol Drug Saf 2005;14:S9.
 
Berger U, Maywald O, Pfirrmann M, Lahaye T, Hochhaus A, Reiter A, Hasford J, Heimpel H, Hossfeld DK, Kolb K-J, Löffler H, Pralle H, Queisser W, Hehlmann R and the German CML-Study Group.
Gender aspects in chronic myeloid leukemia: long-term results from randomized studies.
Leukemia 2005;19:984-989.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM., Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Blood 2005;105:2677-2684.

Hasford J, Pfirrmann M, Hochhaus A.
How long will chronic myeloid leukemia patients treated with Imatinib mesylate live?
Leukemia 2005;19:497-499.

Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B, Eimermacher H, Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
J Clin Oncol 2005;23:1984-1992.

Hasford J, Pfirrmann M, Shepherd P, Guilhot J, Hehlmann R, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J.
The impact of the combination between baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alfa.
Haematologica 2005;90:335-340.

Lenz G, Dreyling M, Schiegnitz E, Haferlach T, Hasford J, Unterhalt M, Hiddemann W.
Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
J Clin Oncol 2004;22:4926-4933.

Strunz-Lehner C, Egen-Lappe V, Hasford J, Janhsen K, Glaeske G.
The Impact of Region and Social Status on Drug Prescribing during Pregnancy.
Pharmacoepi Drug Saf 2004; 13:S182.

Rebhan B, Strunz-Lehner C, Egen-Lappe V, Hasford J, Janhsen K, Glaeske G.
Regional and Social Variation in Iron Prescribing to Pregnant Women.
Pharmacoepi Drug Saf 2004; 13:S180.

Egen-Lappe V, Hasford J, Koethemann M.
Drug Prescription in Pregnancy – Analysis of a Large German Statutory Sickness Fund Population.
Pharmacoepi Drug Saf 2004;13:S152.

Egen-Lappe V, Hasford J, Koethemann M.
Prescription of Homeopathics and Herbal Medicines before and during Pregnancy.
Pharmacoepi Drug Saf 2004;13:S152.

Egen-Lappe V, Hasford J, Koethemann M.
Arzneimittelverordnung in der Schwangerschaft – Analyse von Verordnungsdaten einer großen gesetzlichen Krankenkasse.
J Public Health 2004;12 (Supp. 1):S16-17.

Egen-Lappe V, Hasford J.
Drug prescription in pregnancy: analysis of a large statutory sickness fund population.
Eur J Clin Pharmacol 2004;60:659-666.

Buesche G, Freund M, Hehlmann R, Georgii A, Ganser A, Hecker H, Heimpel H, Fonatsch C, Heinze B, Pfirrmann M, Holgado S, Schmeil A, Tobler A, Hasford J, Buhr T, Kreipe HH: German CML Study Group.
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic resonse: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Leukemia 2004;18:1460-1467.

Dirschedl P, Dugas M, Hasford J, Messerer-Schmid D, Müller TH, Überla K.Biometrie, Epidemiologie und zentrale Informationstechnologie im Kompetenznetz Leukämie.
Med Welt 2004;55:290-293.

Hasford J, Moore N, Hoye K, Milliet Ch, Unkauf M, Magnette J.
Safety and Appropriateness of Use of a Low Dose Analgesic: Methodological Issues and Results of a Pharmacy-Based Cohort Study.
Pharmacoepi Drug Saf 2004; 13:S53-S54.

Hasford J, Moore N and Hoye K.
Safety and usage pattern of low-dose diclofenac when used as an over-the-counter medication: results of an observational cohort study in a community-based pharmacy setting.
Int J Clin Pharm 2004;42:415-422.

Büchner T, Döhner H, Ehninger G, Ganser A, Niederwieser D, Hasford J.
Cross-trial networking in AML: a Stepp forward rather than corner cutting.
Leuk Res 2004;28:649-650.

Hehlmann R, Berger U, Aul C, Büchner , Döhner H, Ehninger G, Ganser A, Gokbuget N, Hoelzer D, Überla k, Gassmann W, Ludwig WD, Rieder H, Kneba M, Hochhaus A, Reiter A, Hiddemann W, Ottmann OG, Germing U, Adelhard K, Dugas M, Dirschedl P, Messerer D, Bohme A, Harrison-Neu E, Griesshammer M, Kienast J, Kolb HJ, Ho AD, Hallek M, Neubauer A, Schlegelberger B, Niederwieser D, Heil G, Müller T, Hasford J.
The German competence network ’Acute and chronic leukemias’.
Leukemia 2004;18:665-669.

Hasford J, Pfirrmann M, Hochhaus A.
How Long Will Chronic Phase CML Patients Treated with Imatinib Live?
Blood 2003;102;11:905a.

Berger U, Hochhaus A, Reiter A, Pfirrmann M, Maywald O, Lahaye T, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queisser W, Hehlmann R, the German CML Study Group.
Gender Specific Issues in Chronic Myelogenous Leukemia (CML): Long-Term Results from Randomized Trials.
Blood 2003;102;11:905a.

Berger U, Hochhaus A, Reiter A, Ehninger G, Fischer T, Gratwohl A, Hasford J, Heimpel H, Hossfeld DK, Kolb H-J, Krause S, Nerl C, Pralle H, Tobler A, Hehlmann R, the German CML Study Group.
Randomized Controlled Comparison of Imatinib vs. Imatinib/Interferon a vs. Imatinib(Low-Dose Ara-C vs. Imatinib after Interferon a Failure in Newly Diagnosed CML: The German CML Study IV – Pilot Phase.
Blood 2003;102;11:904a.

Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A.
Marrow fibrosis, indicator of therapy failure in chronic myeoid leukemia – prospective long-term results from a randomized-controlled trial.
Leukemia 2003;17:2444-53.

Hasford J, Pfirrmann M.
The Combination of Randomized and Historical Controls in the German CML Study II.
Contr Clin Trials 2003;24:124S.

Birkner B, Fritz N, Schatke W, Hasford J.
A prospective randomized comparison of unsedated ultrathin versus standard esophagogastroduodenoscopy in routine outpatient gastroenterelogy practice: does it work better trough the nose?
Endoscopy 2003;35:647-651.

Berger U, Engelich G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Methgeroth G, Gnad U, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H., Queißer, W., Hehlmann, R., and the German CML-Study Group.
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
Leukemia 2003;17:1820-1826.

Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Methgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queißer W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Weiß J, Meier CR, Kremers S, Labedzki L, Schmeiser T, Lohrmann H, Heimpel H, and the German CML-Study Group.
Randomized comparison of interferon a and hydrosyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon a and hydroxyurea.
Leukemia 2003;17:1529-1537.

Hasford J, Fagerstrom O, Haustein K-O.
A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotin patch.
Eur J Clin Pharmacol 2003;59:443-447.

Dugas M, Weinzierl S, Pecar A, Endres S, Hasford J.
Design and implementation of a common drug information database for a university hospital.
Pharm World Sci 2003;25:156-161.

Dugas M, Messerer D, Hasford J, Haferlach T, Heinze B, Ludwig W, Rieder H, Schoch R, Schwartz S, Thiel E.German Multicenter Study Group for Adult ALL (GMALL): recruitment in comparison to ALL incidence and its impact on study results.
Ann Hematol 2003;82:83-87.

Egen V, Hasford J.
Prevention of neural tube defects: effect of an intervention aimed at implementing the official recommendations.
Soz Praventivmed 2003;48:24-32.

Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Thaler J, Steegmann JL, for the Collaborative CML Prognostic Factors Project Group.
Prognosis and Prognostic Factors for Patients With Chronic Myeloid Leukemia: Nontransplant Therapy.
Semin Hematol 2003;40:4-12.

Berger U, Metzgeroth G, Hochhaus A, Hasford J, Maywald O, Engelich G, Heimpel H, Hehlmann R.
Epidemiology of Chronic Myeloid Leukemia and Other Chronic Myeloproliferative Disorders in a Representative Area in the Southwest of Germany.
Blood 2002;100;11:328a.

Reiter A, Maywald O, Metzgeroth G, Berger U, Hochhaus A, Pfirrmann M, Gnad SU, Kolb H-J, Gratwohl ., Bunjes D, Schäfer UW, Zander AR, Finke J, Arnold R, Fauser A, Schwerdtfeger R, Sahakyan L, Hasford J, Hehlmann R.
Favourable Survival of Allogeneic Stem Cell Transplantation after Prior Cytogenetic Response to IFN in Chronic Myelogenous Leukemia (CML).
Blood 2002;100;11:323b.

Hasford J, Pfirrmann M, Shepherd P, Guilhot F, Hehlmann R, Baccarani M, Mahon FX, Kluin-Nelemans HC, Ohnishi K, Steegmann JL, Thaler J, Delannoy A, Kloke O.
Long-Term Survival of Patients with CML: The Role of Hematologic and Cytogenetic Response.
Blood 2002;100;11:785a.

Berger U, Metzgeroth G, Maywald O, Pfirrmann M, Hochhaus A, Reiter A, Engelich G, Hasford J, Heimpel H, Hossfeld .K, Kolb H-J, Löffler H, Pralle H, Queisser W, Hehlmann R.
Randomized Comparison of Interferon/Hydroxyurea vs. Hydroxyurea Monotherapy in Chronic Myeloid Leukemia (CML Study II).
Blood 2002;100;11:371a.

Althaus D, Stefanek J, Hasford J, Hegerl U.
Knowledge and attitude of the general public regarding symptoms, etiology and possible treatments of depressive illnesses.
Nervenarzt 2002;73:659-664.

Hasford J and the Nikon Study Group.
Effectiveness, Safety and Appropriateness of Use of an OTC Nicotine Patch: Results of a Naturalistic Cohort Study on Smoking Cessation.
Pharmacoepidemiol Drug Saf 2002:11:S201.

Egen, V., Roesch, C., Steinbicker, V., Hasford J.
Drug Utilization during Pregnancy – A Comparison between East and West Germany.
Pharmacoepidemiol Drug Saf 2002;11:S148.

Egen V, Hasford J.
Drug Utilization in Pregnancy - Final Report of the Prospective Study ”PEGASUS”.
Pharmacoepidemiol Drug Saf 2002;11:S29.

Schneeweiss S, Hasford J, Göttler M, Hoffmann A, Riethling A-K, Avorn J.
Admissions caused by adverse drug events to internal medicine and emergency departements in hospitals: a longitudinal population-based study.
Eur J Clin Pharmacol 2002;58:285-291.

Hasford J, Mimran A, Simons WR.
A population-based European Cohort Study of Persistence in newly diagnosed hyper-tensive Patients.
J hum Hypertension 2002;16:569-575.

Büchner T, Döhner H, Ehninger G, Ganser A, Hasford, J.
Up-front Randomization and Common Standard Arm: A Proposal for comparing AML Treatment Strategies between different Studies.
Leuk Res 2002;26:1073-5.

MacDonald T, Beard K, Bruppacher R, Hasford J, Lewis M, Logan R, McNaughton D, Parkinson J, Tubert-Bitter P, van Gause E, Moore N.
The Safety of Drugs for OTC Use: what Evidence is required for an NSAID Switch?
Pharmacoepidemiol Drug Saf 2002;7:577-84.

Hasford J, Goettler M, Munter K-M, Müller-Oerlinghausen B.
Physicians' Knowledge and Attitudes regarding the Spontaneous Reporting System for Adverse Drug Reactions.
J Clin Epidemiol 2002;55:945-950.

Pfirrmann M, Hasford J.
Comparison between Sokal Score and New CML Score in a Sample of 493 Patients treated with a Regimen Including Interferon-Alpha.
Hematol J 2001; Vol. I (Suppl. I):23.

Berger U, Hochhaus A, Reiter A, Maywald O, Pfirrmann M, Hasford J, Heinze B, Heimpel H, Hossfeld DK, Kolb H-J, Löffler H, Pralle H, Queißer W, Hehlmann R, and the German CML Study Group.
Interferon-Treatment in the Elderly with Chronic myeloid leukemia (CML). Hematol J 2001; Vol. I (Suppl. I):20.

Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, Hehlmann R, Hochhaus A, Shepherd PC, Steegmann JL, Kluin-Nelemans HC, Thaler J, Simonsson B, Louwagi A, Reiffers J, Mahon FX, Montefusco E, Alimena G, Hasford J, Richards S, Saglio G, Testoni N, Martinelli G, Tura S, Baccarani M.
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074-81.

Hasford J, Pfirrmann M, Hehlmann R, Shepherd P, Guilhot F, Mahon FX, Thaler J, Steegmann JL, Kluin-Nelemans J, Louwagie A, Ohnishi K, Kloke O.
Prognostic Factors. In: Chronic Myeloid Leukemia – Biology and Treatment (A. Carella, G.Q. Daley, CJ Eaves, JM Goldman, R. Hehlmann, eds.), pp.205-223, Martin Dunitz - London (2001).

Schneeweiss S, Göttler M, Hasford J, Swoboda WJ, Hippius M, Hoffmann A-K, Riethling A-K, Krappweiss J.
First results from an intensified monitoring system to estimate drug related hospital admissions.
Br J Clin Pharmacol 2001;52:196-200.

Pfirrmann M, Hasford J.
Testing Sokal's and the The New Prognostic Score for Chronic Myeloid Leukemia treated with a-Interferon: Correspondance.
Br J Haematol 2001;114:241-242.

Swoboda WJ, Göttler M,Zinnhobler K, Hasford, J.
Putting the pieces together: Using "off-the-shelf" software to safely transfer medical data.
Method Inform Med 2001;40:236-240.

Hippius M, Humaid B, Sicker T, Hoffmann A, Göttler M, Hasford J.
Adverse drug reaction monitoring - digitoxin overdosage in the elderly.
Int J Clin Pharmacol Ther 2001;39:336-343.

Hasford J, Mimran A, Simons WR.
Role of Blood Pressure Control for Antihypertensive Persistence: ICE - A population-based European Study.
J Hypertens 2001;19 (Suppl. 2): S.142.

Wildner M, Hasford J, Egen V, Fichter P, Kolominsky-Rabas P, Neundörfer B, Quadflieg N.
Erfolg für die Gesundheit der Bevölkerung: Ausgewählte Projekte aus dem Bayerischen Forschungsverbund Public Health - Öffentliche Gesundheit.
Zeitschrift für Gesundheitswissenschaften - Journal of Public Health 2001;4, Beiheft S. 55-68.

Dugas M, Weinzierl S, Pecar A, Hasford J.
An intranet database for a university hospital drug information center.
Am J Health-Syst Pharm 2001;58:799-802.